secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0000950170-23-051141
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences appoints Lakhmir Chawla to board; Curt LaBelle resigns
-----------------------------------------------------------------------------

- Curt LaBelle M.D. resigned from Board on Sept 27, 2023, not due to any disagreements.
- Lakhmir Chawla M.D. appointed as Class C director to fill vacancy, effective same date.
- Dr. Chawla is CEO of Stavro Medical; former CMO at Silver Creek Pharma and La Jolla Pharmaceutical.
- He will serve on Compensation and Nominations & Corporate Governance Committees.
- No transactions requiring Item 404(a) disclosure between Dr. Chawla and the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023051141/0000950170-23-051141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023051141/revb-20230927.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-051141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer